文献速递预防保健、筛查与疫苗慢病管理

不同新冠疫苗相关血栓伴血小板减少综合征或血栓栓塞事件的比较风险:五欧洲国家和美国的国际网络队列研究

Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US.
PubMed 文献 · BMJ · 2022-10-26

该国际网络队列研究基于法国、德国、荷兰、西班牙、英国和美国常规健康数据,纳入2020年12月至2021年中接种至少一剂新冠疫苗的成人,比较腺病毒载体疫苗与mRNA疫苗在接种后28天内血栓伴血小板减少综合征或血栓栓塞事件的风险。匹配后分析显示,与第一剂BNT162b2相比,ChAdOx1-S第一剂后血小板减少风险合并校准发病率比为1.33(95%CI 1.18至1.50);Ad26.COV2.S相比BNT162b2静脉血栓伴血小板减少综合征的合并校准发病率比为2.26(95%CI 0.93至5.52)。

要点

  • ChAdOx1-S首剂后血小板减少风险较BNT162b2首剂升高约30%。
  • Ad26.COV2.S相比BNT162b2静脉血栓伴血小板减少综合征风险呈升高趋势。
  • 腺病毒载体疫苗相关风险虽罕见,规划免疫策略时仍需考虑。

核心结论

  • 该多国研究观察到ChAdOx1-S首剂后血小板减少风险合并增加30%,Ad26.COV2.S相比BNT162b2静脉血栓伴血小板减少综合征风险呈升高趋势。

研究设计与样本

  • 国际网络队列研究,使用法国、德国、荷兰、西班牙、英国和美国常规收集的健康数据。
  • 纳入2020年12月至2021年中接种至少一剂新冠疫苗的成人(年龄≥18岁)。
  • 采用倾向评分匹配后估计发病率比,并用阴性对照结局校准,数据库特异性估计通过随机效应荟萃分析合并。

主要发现

  • 德国和英国共1 332 719名ChAdOx1-S首剂接种者与2 124 339名BNT162b2接种者匹配。
  • 德国、西班牙和美国共762 517名Ad26.COV2.S接种者与2 851 976名BNT162b2接种者匹配。
  • 美国628 164名Ad26.COV2.S接种者与2 230 157名mRNA-1273接种者匹配。
  • 德国和英国匹配的ChAdOx1-S首剂接种者中观察到862例血小板减少事件,BNT162b2首剂后观察到520例事件。

关键数值与推荐

  • ChAdOx1-S与第一剂BNT162b2相比,血小板减少的合并校准发病率比为1.33(95%CI 1.18至1.50),校准发病率差为每1000人年1.18(0.57至1.8)。
  • Ad26.COV2.S与BNT162b2相比,静脉血栓伴血小板减少综合征的合并校准发病率比为2.26(95%CI 0.93至5.52)。

临床怎么用

  • 在规划后续免疫接种活动和未来疫苗开发时,应考虑腺病毒载体疫苗相关的罕见风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with use of adenovirus based covid-19 vaccines versus mRNA based covid-19 vaccines. DESIGN: International network cohort study. SETTING: Routinely collected health data from contributing datasets in France, Germany, the Netherlands, Spain, the UK, and the US. PARTICIPANTS: Adults (age ≥18 years) registered at any contributing database and who received at least one dose of a covid-19 vaccine (ChAdOx1-S (Oxford-AstraZeneca), BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), or Ad26.COV2.S (Janssen/Johnson & Johnson)), from December 2020 to mid-2021. MAIN OUTCOME MEASURES: Thrombosis with thrombocytopenia syndrome or venous or arterial thromboembolic events within the 28 days after covid-19 vaccination. Incidence rate ratios were estimated after propensity scores matching and were calibrated using negative control outcomes. Estimates specific to the database were pooled by use of random effects meta-analyses. RESULTS: Overall, 1 332 719 of 3 829 822 first dose ChAdOx1-S recipients were matched to 2 124 339 of 2 149 679 BNT162b2 recipients from Germany and the UK. Additionally, 762 517 of 772 678 people receiving Ad26.COV2.S were matched to 2 851 976 of 7 606 693 receiving BNT162b2 in Germany, Spain, and the US. All 628 164 Ad26.COV2.S recipients from the US were matched to 2 230 157 of 3 923 371 mRNA-1273 recipients. A total of 862 thrombocytopenia events were observed in the matched first dose ChAdOx1-S recipients from Germany and the UK, and 520 events after a first dose of BNT162b2. Comparing ChAdOx1-S with a first dose of BNT162b2 revealed an increased risk of thrombocytopenia (pooled calibrated incidence rate ratio 1.33 (95% confidence interval 1.18 to 1.50) and calibrated incidence rate difference of 1.18 (0.57 to 1.8) per 1000 person years). Additionally, a pooled calibrated incidence rate ratio of 2.26 (0.93 to 5.52) for venous thrombosis with thrombocytopenia syndrome was seen with Ad26.COV2.S compared with BNT162b2. CONCLUSIONS: In this multinational study, a pooled 30% increased risk of thrombocytopenia after a first dose of the ChAdOx1-S vaccine was observed, as was a trend towards an increased risk of venous thrombosis with thrombocytopenia syndrome after Ad26.COV2.S compared with BNT162b2. Although rare, the observed risks after adenovirus based vaccines should be considered when planning further immunisation campaigns and future vaccine development.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Li X, Burn E, Duarte-Salles T, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US. BMJ. 2022. PMID: 36288813. doi:10.1136/bmj-2022-071594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。